RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients with Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

F-18-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients

Comparing Retreatment of Lu-177-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

Study in Children and Adolescents of Lu-177-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). (LUPARPED)

A Study of Lu-177-DTPA-SC16.56 in People with Neuroendocrine Carcinomas of the Lung and Prostate

A Phase Ib/II Open-label Study of AMO959 with Lutetium (Lu-177) Vipivotide Tetraxetan (AAA617) in Combination with ARPI in Adult Participants with PSMA-positive mCRPC

Lu-177-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (LuPARP)

Radium-223 in Combination with Enzalutamide

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used with Targeted Radiation-based Treatment (Lutetium Lu-177 Dotatate), Compared to Lutetium Lu-177 Dotatate Alone for Metastatic Neuroendocrine Tumors